Avalo Therapeutics vs Cervomed
Cervomed is the larger business, with $4.0m of revenue in fiscal 2025 against $59,000 for Avalo Therapeutics (67.9 times as much). Cervomed grew faster (-58.9% against -86.6%). Cervomed kept more of each dollar of sales as profit: a net margin of -673.1% against -132642.4%. Avalo Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Avalo TherapeuticsAVTX, 2025 | CervomedCRVO, 2025 |
|---|---|---|
| Revenue | $59,000 | $4.0m |
| Revenue growth | -86.6% | -58.9% |
| Net income | −$78.3m | −$27.0m |
| Operating margin | -123601.7% | -706.2% |
| Net margin | -132642.4% | -673.1% |
| Return on equity | -72.4% | -93.9% |
| Free cash flow | −$51.5m | −$23.4m |
| Cash | $15.9m | $8.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 33 | 15 |
| Market value | $383m | $21.0m |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | — |
| Insider trades, 12 months | 0 buys, 43 sales | 19 buys, 0 sales |